Abbott Laboratories (NYSE: ABT) – Medical Devices, Diagnostics, Nutrition, Pharmaceuticals

NYSE: ABT | Market Cap: ~$200 billion USD | Sector: Healthcare/Medical Devices

Company Overview

Abbott Laboratories is a global healthcare leader with a diversified portfolio spanning medical devices, diagnostics, nutrition products, and established pharmaceuticals. Founded over 135 years ago, Abbott has evolved into one of the most innovative and financially stable healthcare companies, known for breakthrough technologies like FreeStyle Libre (continuous glucose monitoring) and life-saving cardiovascular devices.

Key Facts

Founded: 1888 by Dr. Wallace Calvin Abbott in Chicago
Headquarters: Abbott Park, Illinois, USA
NYSE Listing: 1929
CEO: Robert B. Ford (since 2020)
Employees: 115,000+ globally
Operations: 160+ countries
Manufacturing: 100+ facilities worldwide
Market Position: Top 10 global medical device company, #1 in continuous glucose monitoring
Dividend Aristocrat: 52+ consecutive years of dividend increases

Corporate Structure Evolution

AbbVie Spin-Off (2013)

Abbott separated its research-based pharmaceutical business into AbbVie (NYSE: ABBV)
AbbVie took Humira and other branded drugs
Abbott retained medical devices, diagnostics, nutrition, and generic pharmaceuticals
Rationale: Focus on faster-growing, less patent-dependent businesses
Result: Both companies thrived independently (combined market cap $520B+)

Post-Spin Strategy

Focus on durable, recurring revenue businesses
Geographic diversification (50%+ revenue from emerging markets)
Innovation in medical technology (FreeStyle Libre, structural heart devices)
Bolt-on acquisitions (St. Jude Medical $25B, Alere $5.3B)

Business Segments

Revenue by Segment (FY2023)

Segment	Revenue	% of Total	Growth Rate
Medical Devices	$17.8B	44%	+12.5%
Diagnostics	$9.3B	23%	-11.2% (COVID decline)
Nutrition	$8.2B	20%	+7.8%
Established Pharma	$5.2B	13%	+4.1%

Total Revenue: $40.1 billion (2023)

1. Medical Devices (~44% of revenue)

Revenue: $17.8 billion (2023)

Abbott’s largest and fastest-growing segment, encompassing cardiovascular devices, diabetes care, neuromodulation, and structural heart technologies.

Diabetes Care (~$5.5B revenue)

FreeStyle Libre® – Continuous Glucose Monitoring (CGM)

Technology

Sensor: Small wearable device on back of upper arm
Duration: 14 days (Libre 2, Libre 3), 15 days (Libre Rio)
Measurement: Interstitial fluid glucose levels
Reading: Scan with smartphone or reader (Libre 2), real-time continuous (Libre 3)
No fingersticks: Eliminates need for routine blood glucose testing
Alarms: High/low glucose alerts (Libre 2, Libre 3)

Product Portfolio

FreeStyle Libre 3: World’s smallest, thinnest CGM sensor (5mm diameter)
FreeStyle Libre 2: Most widely used CGM globally
FreeStyle Libre Rio: Affordable version for emerging markets
Lingo: Consumer biowearable for general wellness (launched 2024)

Market Position

#1 global CGM: 5+ million users worldwide
Market share: ~50% global CGM market
Sales: $5.5 billion (2023), growing 25%+ annually
Geography: Available in 60+ countries
Reimbursement: Covered by Medicare, Medicaid, private insurance in US; NHS in UK; expanding globally

Competitive Advantages

✅ No fingersticks: Factory-calibrated (vs Dexcom requiring calibration)
✅ Lower cost: $75-100/month vs $300+ for Dexcom
✅ Ease of use: Simple application, smartphone integration
✅ Global reach: Strong presence in Europe, emerging markets
✅ Type 2 diabetes focus: Expanding beyond Type 1 (larger market)

Growth Drivers

Type 2 diabetes expansion: 90% of diabetes patients (vs 10% Type 1)
Emerging markets: China, India, Latin America adoption
Reimbursement expansion: More insurance coverage globally
Technology upgrades: Libre 3 adoption, integration with insulin pumps
Consumer wellness: Lingo for non-diabetics (metabolic health tracking)

Competition

Dexcom: G7 CGM (real-time, more accurate, but more expensive)
Medtronic: Guardian CGM (integrated with insulin pumps)
Insulet: Omnipod 5 (tubeless insulin pump with Dexcom integration)

Cardiovascular Devices (~$6.5B revenue)

Structural Heart

MitraClip® – Transcatheter Mitral Valve Repair

Indication: Mitral regurgitation (leaky heart valve)
Technology: Minimally invasive clip delivered via catheter (no open-heart surgery)
Sales: $1.5 billion (2023)
Market position: #1 transcatheter mitral valve therapy
Growth: 15%+ annually
Expansion: Tricuspid valve repair (TriClip®) approved 2023

Transcatheter Aortic Valve Replacement (TAVR)

Portico™ valve: Self-expanding TAVR system
Navitor™ valve: Next-generation TAVR (launched 2022)
Sales: $800 million (2023)
Competition: Edwards Lifesciences (Sapien), Medtronic (CoreValve) dominate market
Strategy: Gaining share with Navitor technology

Left Atrial Appendage Closure (LAAC)

Amulet™: Device to prevent stroke in atrial fibrillation patients
Sales: $500 million (2023)
Competition: Boston Scientific (Watchman) market leader

Electrophysiology (EP)

Cardiac Ablation

TactiCath™: Contact force-sensing ablation catheter
EnSite X™: 3D cardiac mapping system for atrial fibrillation ablation
FlexAbility™: Steerable ablation catheter
Sales: $1.2 billion (2023)
Market: Growing due to increasing AFib prevalence

Heart Failure

CardioMEMS™ HF System

Technology: Wireless pulmonary artery pressure sensor
Indication: Heart failure monitoring (prevents hospitalizations)
Implantation: Minimally invasive catheter-based procedure
Monitoring: Daily pressure readings transmitted to physician
Sales: $300 million (2023)
Growth: 30%+ annually
Evidence: 33% reduction in heart failure hospitalizations (CHAMPION trial)

Vascular Devices

Xience™ family: Drug-eluting stents (coronary artery disease)
Supera™: Peripheral vascular stents
Absorb™: Bioresorbable vascular scaffold (dissolving stent)
Sales: $2.5 billion (2023)

Neuromodulation (~$1.2B revenue)

Chronic Pain Management

Proclaim™ Plus Spinal Cord Stimulation (SCS)

Technology: Rechargeable neurostimulator for chronic pain
BurstDR™ stimulation: Proprietary waveform for pain relief
Indications: Failed back surgery syndrome, complex regional pain syndrome, diabetic neuropathy
Competition: Medtronic, Boston Scientific, Nevro

Eterna™ SCS System

Smallest rechargeable SCS: Longest battery life (10+ years)
Launched: 2023
Advantage: Fewer recharge sessions, smaller profile

Movement Disorders

Infinity™ Deep Brain Stimulation (DBS)

Indications: Parkinson’s disease, essential tremor, dystonia, epilepsy
Technology: Directional leads for precise stimulation
Competition: Medtronic (market leader), Boston Scientific

Heart Rhythm Management (~$1.5B revenue)

Pacemakers & Defibrillators

Aveir™ VR: Leadless pacemaker (no wires, implanted directly in heart)
Aveir™ DR: Dual-chamber leadless pacemaker (world’s first, approved 2023)
Gallant™: Implantable cardioverter defibrillator (ICD)
Quadra Assura MP™: Cardiac resynchronization therapy (CRT) device

Leadless Pacemaker Advantage

No surgical pocket or leads (reduces infection risk)
Faster recovery, less invasive
Dual-chamber capability (Aveir DR) – industry first
Market potential: $4B+ global pacemaker market

2. Diagnostics (~23% of revenue)

Revenue: $9.3 billion (2023, down from $16.5B in 2021 due to COVID testing decline)

Core Laboratory Diagnostics (~$4.5B revenue)

Alinity™ Platform

Alinity i: Immunoassay analyzer (hormones, tumor markers, infectious disease)
Alinity c: Clinical chemistry analyzer (metabolic panels, liver/kidney function)
Alinity h: Hematology analyzer (blood cell counts)
Alinity s: Blood and plasma screening (blood bank testing)

ARCHITECT™ Platform

Legacy immunoassay and chemistry systems
Installed base: 20,000+ systems globally
Recurring revenue: Reagents, consumables

Business Model

Razor-blade model: Place instruments, sell high-margin reagents
Long-term contracts: 5-10 year agreements with hospitals/labs
Recurring revenue: 80%+ of diagnostics revenue from consumables

Molecular Diagnostics (~$2.0B revenue)

Alinity m™ Molecular System

Applications: Infectious disease testing (HIV, hepatitis, STIs, respiratory viruses)
Technology: Real-time PCR
Throughput: High-volume automated testing

ID NOW™ Platform

Point-of-care molecular testing: Rapid results (5-13 minutes)
Tests: COVID-19, flu, strep, RSV
Setting: Physician offices, urgent care, pharmacies
Installed base: 40,000+ systems in US

BinaxNOW™ COVID-19 Tests

Rapid antigen test: 15-minute results, at-home use
Peak sales: $7.7 billion (2021) during COVID surge
Current sales: ~$500 million (2023) – endemic market
Distribution: Retail (CVS, Walgreens), government contracts

Point-of-Care Testing (~$1.8B revenue)

i-STAT™ Handheld Analyzer

Applications: Blood gas, electrolytes, cardiac markers, coagulation
Settings: Emergency rooms, ICUs, operating rooms, ambulances
Advantage: Results in minutes at patient bedside
Installed base: 80,000+ systems globally

Afinion™ System

Tests: HbA1c (diabetes), lipid panel, CRP (inflammation)
Setting: Physician offices, clinics

Rapid Diagnostics (~$1.0B revenue)

Lateral Flow Tests

Panbio™: COVID-19, malaria, dengue rapid tests
Determine™: HIV, syphilis, TB rapid tests
Markets: Emerging markets, public health programs

3. Nutrition (~20% of revenue)

Revenue: $8.2 billion (2023)

Pediatric Nutrition (~$4.5B revenue)

Infant Formula

Similac®

Market position: #1 infant formula brand in US
Product lines:
- Similac Pro-Advance: Closest to breast milk (2′-FL HMO)
- Similac Pro-Sensitive: For sensitive stomachs
- Similac Alimentum: Hypoallergenic formula
- Similac NeoSure: Premature infant formula
Innovation: Human milk oligosaccharides (HMO) for immune support
Distribution: Retail, hospitals, WIC program

PediaSure®

Indication: Nutritional supplement for picky eaters, growth support
Market: Children 1-13 years
Sales: $1.5 billion globally

Challenges (2022-2023)

Formula shortage: Sturgis, Michigan plant shutdown (contamination concerns)
Recall: Voluntary recall of certain Similac products (Feb 2022)
Market share loss: Temporary decline during shortage
Recovery: Plant reopened, market share stabilizing (2023-2024)

Adult Nutrition (~$3.7B revenue)

Ensure®

Market position: #1 adult nutritional supplement globally
Target: Older adults, malnutrition, post-surgery recovery
Product lines:
- Ensure Original: Complete balanced nutrition
- Ensure Plus: High-calorie for weight gain
- Ensure Max Protein: 30g protein per serving
- Ensure Enlive: Advanced nutrition with HMB (muscle health)
Sales: $2.5 billion globally

Glucerna®

Indication: Diabetes-specific nutrition (slow-release carbs)
Market: Type 2 diabetes patients
Sales: $800 million

Specialty Nutrition

Nepro®: Kidney disease nutrition
Juven®: Wound healing support
Pulmocare®: Respiratory disease nutrition

4. Established Pharmaceuticals (~13% of revenue)

Revenue: $5.2 billion (2023)

Generic and branded generic pharmaceuticals in emerging markets (India, Latin America, Asia, Middle East, Africa).

Therapeutic Areas

Gastroenterology

Creon®: Pancreatic enzyme replacement (cystic fibrosis, pancreatitis)
Dexilant®: Proton pump inhibitor (GERD, acid reflux)
Sales: $1.5 billion combined

Women’s Health

Duphaston®: Hormone therapy (menstrual disorders, pregnancy support)
Femoston®: Hormone replacement therapy (menopause)
Sales: $800 million

Central Nervous System

Brufen®: Ibuprofen (pain, inflammation)
Serc®: Vertigo treatment
Sales: $600 million

Cardiometabolic

Lipanthyl®: Cholesterol management
Teveten®: Hypertension
Sales: $500 million

Other

Antibiotics, pain management, respiratory drugs
Branded generics portfolio (1,000+ products)

Geographic Focus

India: $1.5 billion (largest market)
Latin America: $1.2 billion
Asia (ex-India): $1.0 billion
Middle East/Africa: $800 million
Europe: $700 million

Strategy

Focus on emerging markets (faster growth, less competition)
Local manufacturing and distribution
Branded generics command premium to pure generics
Stable, cash-generative business

Geographic Revenue Mix

Revenue by Region (FY2023)

Region	Revenue	% of Total	Growth Rate
United States	$19.2B	48%	+8.5%
International	$20.9B	52%	+5.2%
– Developed Markets	$10.5B	26%	+4.1%
– Emerging Markets	$10.4B	26%	+6.5%

Emerging Markets Strength

26% of revenue: Higher than most US healthcare companies
Key markets: China, India, Brazil, Russia, Middle East
Growth: 2x developed market growth rates
Products: Nutrition (Ensure, PediaSure), established pharma, diagnostics

Competitive Landscape

Medical Devices

Diabetes Care

Dexcom: G7 CGM (real-time, more accurate, premium pricing)
Medtronic: Guardian CGM + insulin pump integration
Abbott advantage: Lower cost, no fingersticks, global reach

Cardiovascular

Medtronic: Largest cardiovascular device company
Boston Scientific: Strong in EP, structural heart
Edwards Lifesciences: TAVR market leader
Abbott position: #2-3 in most cardiovascular categories, #1 in mitral valve repair

Neuromodulation

Medtronic: Market leader in SCS and DBS
Boston Scientific: Strong in SCS
Nevro: High-frequency SCS specialist
Abbott position: #3-4, gaining share with Eterna

Diagnostics

Core Lab

Roche Diagnostics: Market leader
Siemens Healthineers: Strong in chemistry, immunoassay
Danaher (Beckman Coulter): Automation leader
Abbott position: #2-3 globally, strong in immunoassay

Point-of-Care

Abbott: Market leader with i-STAT
Roche: cobas Liat, Accu-Chek
Siemens: Epoc, RAPIDPoint

Nutrition

Infant Formula

Abbott (Similac): #1 in US (~40% share)
Reckitt (Mead Johnson/Enfamil): #2 in US (~35% share)
Nestlé (Gerber): #3 in US (~15% share)
Danone (Aptamil): Strong in Europe, China

Adult Nutrition

Abbott (Ensure): Global leader
Nestlé Health Science (Boost): #2 globally
Danone (Nutricia): Strong in Europe

Financial Performance

Revenue Trends

Year	Revenue	Growth	Notes
2019	$31.9B	+7.7%	Pre-COVID baseline
2020	$34.6B	+8.5%	COVID testing ramp-up
2021	$43.1B	+24.5%	COVID testing peak
2022	$43.7B	+1.4%	COVID plateau
2023	$40.1B	-8.2%	COVID decline, base business +13%
2024E	$41-42B	+3-5%	Stabilization

Organic Growth (Excluding COVID Testing)

2023: +13.0% (strong underlying business)
Medical Devices: +12.5% (FreeStyle Libre +25%)
Nutrition: +7.8% (recovery from formula shortage)
Established Pharma: +4.1% (emerging markets growth)

Profitability Metrics (FY2023)

Gross margin: 56.8%
Operating margin: 19.2%
Net profit margin: 14.8%
Adjusted net profit margin: 18.5%
Return on equity (ROE): 16.2%
EBITDA: $10.2 billion
EBITDA margin: 25.4%

Earnings Per Share

Reported EPS: $3.37 (2023)
Adjusted EPS: $4.44 (2023)
2024 guidance: $4.50-$4.70 adjusted EPS
Long-term growth: 10%+ adjusted EPS growth target

Dividend History

Annual dividend: $2.16 per share (2024)
Dividend yield: 1.8-2.0%
Payout ratio: ~48% of adjusted earnings
Dividend Aristocrat: 52+ consecutive years of increases
Dividend growth: 12%+ annually (10-year average)
Quarterly payments: February, May, August, November

Balance Sheet (FY2023)

Total assets: $88.7 billion
Cash and investments: $11.2 billion
Total debt: $18.9 billion
Net debt: $7.7 billion
Debt/EBITDA: 0.8x (very low leverage)
Credit rating: A+ (S&P), A1 (Moody’s) – strong investment grade

Cash Flow (FY2023)

Operating cash flow: $8.9 billion
Free cash flow: $7.4 billion
Capex: $1.5 billion (~3.7% of revenue)
Cash conversion: 125% of net income

Capital Allocation (FY2023)

Dividends: $3.8 billion
Share buybacks: $2.5 billion
Total shareholder returns: $6.3 billion (85% of free cash flow)
M&A: $500 million (bolt-on acquisitions)
R&D: $2.9 billion (~7% of revenue)

Investment Thesis

Bull Case 🐂

FreeStyle Libre Growth Engine

$5.5B sales (2023): Growing 25%+ annually
Market expansion: Type 2 diabetes (90% of diabetes patients)
Global opportunity: 537 million diabetics worldwide, <5% using CGM
Reimbursement expansion: More insurance coverage globally
Technology leadership: Libre 3 smallest, thinnest CGM
Peak sales potential: $10-15 billion by 2030

Diversified, Durable Revenue

Four segments: Medical devices, diagnostics, nutrition, pharma
Recurring revenue: 70%+ from consumables, reagents, nutrition
Geographic diversification: 52% international, 26% emerging markets
Recession-resistant: Healthcare spending non-discretionary

Structural Heart Leadership

MitraClip: #1 transcatheter mitral valve repair ($1.5B sales)
TriClip: Tricuspid valve repair (approved 2023, new market)
Navitor TAVR: Gaining share in aortic valve market
Aging population: Increasing valve disease prevalence
Market growth: 10-15% annually

Dividend Aristocrat Quality

52+ years: Consecutive dividend increases
12%+ growth: Annual dividend growth (10-year average)
Sustainable payout: ~48% of earnings
Strong cash flow: $7.4B free cash flow supports dividend
Income + growth: Attractive for dividend investors

Innovation Pipeline

Aveir DR: World’s first dual-chamber leadless pacemaker
Lingo: Consumer biowearable for metabolic health (non-diabetics)
CardioMEMS: Heart failure monitoring (30%+ growth)
Libre 4: Next-generation CGM in development
R&D investment: $2.9B annually (7% of revenue)

Emerging Markets Exposure

26% of revenue: Higher than most US healthcare companies
Faster growth: 2x developed market rates
Rising middle class: Increasing healthcare spending in China, India, Latin America
Local presence: Manufacturing, distribution in key markets

Post-COVID Stabilization

Base business strong: +13% organic growth (ex-COVID, 2023)
COVID testing normalizing: $500M run-rate (vs $7.7B peak)
Valuation reset: Stock down 20% from 2021 peak (buying opportunity)
Margin expansion: Operating leverage as revenue grows

Financial Strength

Low leverage: 0.8x debt/EBITDA
Strong cash flow: $7.4B free cash flow
Capital allocation: 85% of FCF returned to shareholders
M&A capacity: Balance sheet supports bolt-on acquisitions

Bear Case 🐻

Risks and Challenges

FreeStyle Libre Competition

Dexcom G7: More accurate, real-time data, gaining share
Medtronic: Integrated CGM + insulin pump systems
Pricing pressure: Competition driving down CGM prices
Reimbursement risk: Insurance coverage could be cut
Technology risk: Non-invasive CGM (no sensor) in development by competitors

Infant Formula Challenges

2022 recall: Sturgis plant shutdown, market share loss
Reputation damage: Safety concerns impacting brand trust
Competition: Reckitt (Enfamil) gaining share
Declining birth rates: US, Europe, China birth rates falling
Breastfeeding advocacy: WHO/UNICEF promoting breastfeeding over formula

COVID Testing Revenue Cliff

Peak (2021): $7.7 billion BinaxNOW sales
Current (2023): ~$500 million (93% decline)
Difficult to replace: $7B revenue loss
Margin impact: COVID tests had high margins

Cardiovascular Device Competition

TAVR: Edwards Lifesciences, Medtronic dominate (Abbott #3)
Electrophysiology: Intense competition (Biosense Webster, Medtronic)
Pacemakers: Medtronic market leader in leadless pacemakers
Pricing pressure: Hospitals demanding lower device prices

Regulatory & Reimbursement Risk

Medical device tax: 2.3% excise tax (suspended, could return)
Medicare cuts: Potential reimbursement reductions
FDA scrutiny: Increased regulatory oversight post-formula recall
International price controls: Europe, Japan, China limiting device prices

Emerging Markets Volatility

Currency risk: 26% of revenue in emerging markets (FX fluctuations)
Political instability: Russia, Middle East, Latin America risks
Economic slowdown: China growth slowing
Local competition: Domestic companies in India, China

Valuation

Premium multiple: Trading at 25-28x P/E (above historical average)
High expectations: FreeStyle Libre growth priced in
Limited upside: Stock near all-time highs
Dividend yield: 1.8-2.0% (lower than some peers)

Execution Risk

Product launches: Aveir DR, Lingo adoption uncertain
Manufacturing: Formula recall highlighted quality control issues
Integration: St. Jude Medical acquisition (2017) still being optimized

Valuation Metrics

Current Trading Multiples (indicative)

P/E Ratio: 25-28x
Forward P/E: 23-25x
Price-to-Sales: 4.8-5.2x
Price-to-Book: 4.5-5.0x
EV/EBITDA: 20-22x
Dividend Yield: 1.8-2.0%

Comparison to Peers

Company	P/E	Div Yield	Market Cap	Key Strengths
Abbott	26x	1.9%	$200B	FreeStyle Libre, diversification, dividend aristocrat
Medtronic	16x	3.4%	$110B	Cardiovascular, diabetes, neuro leader
Dexcom	65x	0%	$45B	CGM pure-play, high growth
Boston Scientific	30x	0%	$130B	Cardiovascular, EP, structural heart
Stryker	28x	1.0%	$140B	Orthopedics, surgical equipment
Becton Dickinson	18x	1.4%	$70B	Medical devices, diagnostics

Observation: Abbott trades at premium to diversified device companies, reflecting FreeStyle Libre growth and dividend aristocrat status

Key Catalysts to Monitor

Near-Term (2026)

Quarterly earnings: FreeStyle Libre growth, base business trends
Libre 3 adoption: US launch momentum, international expansion
Lingo launch: Consumer biowearable market reception
Aveir DR uptake: Dual-chamber leadless pacemaker adoption
Formula market share: Recovery from 2022 recall

Medium-Term (2027-2028)

FreeStyle Libre 4: Next-generation CGM launch
Type 2 diabetes expansion: Reimbursement and market penetration
TriClip growth: Tricuspid valve repair market development
Emerging markets: China, India growth acceleration
M&A activity: Bolt-on acquisitions in high-growth areas

Long-Term (2029+)

CGM market maturity: 20-30% penetration of diabetes patients
Structural heart expansion: New valve therapies, earlier interventions
Consumer health: Lingo and wellness products scaling
Diagnostics innovation: AI-powered diagnostics, decentralized testing

How to Invest in Abbott Laboratories

Direct Stock Purchase

NYSE: ABT – New York Stock Exchange
Available through US and international brokers
Dividend Reinvestment Plan (DRIP) available
Highly liquid – easy to buy/sell

ETF Exposure

Health Care Select Sector SPDR (XLV) – ~4% ABT weighting
iShares U.S. Healthcare ETF (IYH) – ~3% ABT weighting
Vanguard Health Care ETF (VHT) – ~3% ABT weighting
SPDR S&P Dividend ETF (SDY) – Dividend Aristocrat exposure
Vanguard Dividend Appreciation ETF (VIG) – Dividend growth focus

Dividend Reinvestment

Automatic reinvestment of dividends to buy more shares
Commission-free through Abbott’s DRIP program
Compound growth over time

Analyst Consensus (Indicative)

Ratings Distribution

Buy: 60% of analysts
Hold: 38% of analysts
Sell: 2% of analysts

Price Target Range

Bull case: $135-145 USD
Base case: $120-130 USD
Bear case: $100-110 USD

Note: Analyst opinions vary based on FreeStyle Libre growth assumptions, Dexcom competition, and emerging markets outlook

Tax Considerations (US Investors)

Dividends

Qualified dividends: Taxed at long-term capital gains rates (0%, 15%, or 20%)
Holding period: Must hold stock 60+ days around ex-dividend date
Tax-advantaged accounts: IRA, 401(k) dividends grow tax-deferred

Capital Gains

Long-term: Held 12+ months, taxed at 0%, 15%, or 20%
Short-term: Held less than 12 months, taxed as ordinary income

International Investors

Withholding tax: 30% US tax on dividends (reduced by tax treaty)
Australian investors: 15% withholding under US-Australia tax treaty
Foreign tax credit: Can claim credit in home country

ESG Considerations

Environmental

Carbon neutrality goal: Net-zero emissions by 2050
Renewable energy: 100% renewable electricity by 2030
Water stewardship: Reducing water usage in manufacturing
Sustainable packaging: Recyclable materials, reducing plastic
Product lifecycle: Designing for recyclability

Social

Access to healthcare: Affordable products in emerging markets
Nutrition programs: Malnutrition initiatives in developing countries
Diversity and inclusion: 50%+ workforce women, diverse leadership
Employee health: Comprehensive benefits, mental health support
Community engagement: Abbott Fund charitable giving ($100M+ annually)

Governance

Independent board (11 of 12 directors independent)
Separate CEO and Chairman roles
Executive compensation tied to long-term performance and ESG metrics
Transparent financial reporting
Strong regulatory compliance programs

ESG Controversies

2022 formula recall: Safety and quality control concerns
Infant formula marketing: Criticism of marketing in developing countries
Device pricing: High US prices vs international

ESG Ratings: Generally strong scores, but formula recall impacted 2022-2023 ratings

Related Terms

Continuous Glucose Monitoring (CGM) – Real-time glucose tracking without fingersticks
Transcatheter valve therapy – Minimally invasive heart valve repair/replacement
Spinal cord stimulation (SCS) – Implanted device for chronic pain management
Deep brain stimulation (DBS) – Implanted device for movement disorders
Leadless pacemaker – Pacemaker without wires, implanted directly in heart
Point-of-care testing – Diagnostic testing at patient bedside
Human milk oligosaccharides (HMO) – Prebiotic compounds in breast milk (added to formula)
Immunoassay – Laboratory test using antibodies to detect substances
Electrophysiology (EP) – Study and treatment of heart rhythm disorders
Structural heart disease – Abnormalities in heart valves or chambers

Disclaimer: This information is for educational purposes only and does not constitute financial or medical advice. Abbott Laboratories stock carries risks including competitive pressures (Dexcom, Medtronic), product recalls, regulatory changes, reimbursement cuts, emerging markets volatility, and execution challenges. DYOR before making investment decisions. Past performance is not indicative of future results. Consult with financial advisors regarding investment decisions and healthcare professionals regarding medical products.

Official Website: www.abbott.com

Investor Relations: investors.abbott.com

NYSE Listing: www.nyse.com (Code: ABT)

SEC Filings: www.sec.gov (Search: Abbott Laboratories)

Related Topics: Abbott Laboratories, NYSE:ABT, Medical Device Stocks, FreeStyle Libre, Continuous Glucose Monitoring, CGM, Diabetes Care, Cardiovascular Devices, MitraClip, Diagnostics, Infant Formula, Similac, Ensure, Nutrition, Dividend Aristocrat, Dividend Stocks, Healthcare Stocks, Emerging Markets, Structural Heart, Neuromodulation, Point-of-Care Testing, AbbVie Spin-Off

Uninformed Investors